Book Appointment

New FDA Warning: GLP-1 Medications and a Rare Eye Condition (NAION)

Patient notice · Eye health · Buitique Optometry

On November 9, 2026, the U.S. Food and Drug Administration (FDA) announced that all GLP-1 medications, which are widely used for type 2 diabetes and weight loss, must carry a new safety warning. The warning is about a possible increased risk of a rare eye condition called NAION (non-arteritic anterior ischemic optic neuropathy).

Because your eye health is our priority, we want you to know what this means, what to watch for, and when to call us.

What is NAION?

  • It happens when blood flow to the front of the optic nerve suddenly drops. It is sometimes called an “eye stroke.”
  • It usually affects one eye.
  • It causes sudden, painless vision loss, which can be permanent.
  • It is rare. In the FDA’s review of 126 clinical trials, NAION occurred in about 6.4 people per 100,000 per year on GLP-1 medications, compared with 3.8 per 100,000 on a placebo or other diabetes medications.

Which medications are included?

The warning applies to every GLP-1 medication, including:

  • Ozempic, Wegovy, Rybelsus (semaglutide)
  • Mounjaro, Zepbound (tirzepatide)
  • Trulicity (dulaglutide)
  • Victoza, Saxenda, Xultophy (liraglutide)
  • Foundayo (orforglipron)
  • Exenatide and Soliqua (lixisenatide with insulin glargine)

Warning signs: contact us right away if you notice

  • Sudden blurry, dim, or cloudy vision in one eye
  • Blind spots, missing patches, or tunnel vision
  • Colors looking faded or washed out

Sudden vision loss is an emergency. If you cannot reach us, go to the nearest emergency room.

What we recommend

  • Do not stop or change your medication on your own. These medications have important health benefits. Talk to your prescribing doctor before making any changes.
  • Tell us if you take a GLP-1 medication so we can note it in your records and monitor your eye health.
  • Schedule a comprehensive dilated eye exam, especially if you also have diabetes, high blood pressure, sleep apnea, kidney disease, anemia, or a history of smoking. These are known risk factors for NAION.
  • If you have had NAION before, the FDA advises talking with your doctor about whether to continue your GLP-1 medication.

We are here to help

Questions about your vision or your medication’s effect on your eyes? Our team is happy to help.

Call or text 858-531-8541 · Office 619-464-8303
5020 Baltimore Drive, Suite B, La Mesa, CA 91942

Book an Eye Exam

Warm regards,
Dr. Tina Bui and the Buitique Optometry Team

Sources: U.S. Food and Drug Administration, Drug Safety Communication, November 9, 2026; Vision Monday; Pharmacy Times.

This article is for general information and is not a substitute for advice from your own doctor.

Leave a Comment

Your email address will not be published. Required fields are marked *